NFL Biosciences SA (ENXTPA: ALNFL)
Health Care · Biotechnology · FR
€0.83
-4.37% today · -46.0% 1Y
NFL Biosciences SA (ENXTPA: ALNFL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $12.21M and employs 4 people.
Over the last twelve months the share price has lost 46.0%, trading between 0.80 and 1.85.
Tweenvest scores NFL Biosciences SA across four factors: quality 31/100. Its strongest factor is quality.
ALNFL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $12.21M
- Revenue (TTM)
- $221.00
- P/E
- —
- EPS
- -0.26
- Dividend yield
- —
- Beta (5Y)
- 1.15
- 52-week high
- €1.85
- 52-week low
- €0.80
- Avg volume (3M)
- —
- Shares outstanding
- 12.67M
- Employees
- 4
- Next earnings
- —
About NFL Biosciences SA
Established in 2006 and headquartered in Castelnau-le-Lez, France, NFL Biosciences S.A. is a biotechnology enterprise dedicated to pioneering natural remedies for addiction cessation, particularly for individuals seeking to quit smoking. Their most advanced therapeutic candidate, NFL-101, derived from tobacco, is currently progressing through Phase III clinical trials specifically designed to combat smoking addiction. Additionally, the company's research pipeline features NFL-201, an extract blending cannabis and tobacco, and NFL-301, a botanical formulation rooted in traditional Chinese medicine, both of which are undergoing preclinical assessment.
- ISIN
- FR0014003XT0
- Founded
- 2006
- Listed since
- Jul 5, 2021
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $265.43 | +0.18% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.98 | +0.38% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.44 | +0.22% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.78 | +0.13% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $825.89 | -0.98% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $139.44 | -3.88% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.